COMMUNIQUÉS West-GlobeNewswire

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
23/01/2026
OCALA, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to [...]
Aja Health and Wellness Inc. Announces Agreement Between Assured Diagnosis Inc. and Greatway Financial Inc. and Implementation of New Electronic Medical Records Software for GOeVisit
23/01/2026
Not for dissemination in the United States of America VANCOUVER, British Columbia, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that its wholly-owned [...]
20 Million Patients Benefit from da Vinci Surgery Globally
23/01/2026
Achievement reflects the dedication of surgeons and care teams worldwide to improving patient outcomes through use of Intuitive’s minimally invasive technologies SUNNYVALE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- [...]
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
23/01/2026
LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
23/01/2026
Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months [...]
NextCure Provides Business Update
23/01/2026
SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026 LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc [...]
Sanara MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial Guidance
23/01/2026
FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and [...]
AMN Healthcare to Hold Fourth Quarter and Full Year 2025 Earnings Conference Call on Thursday, February 19, 2026
23/01/2026
DALLAS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its fourth quarter and full year 2025 financial results and first quarter 2026 outlook on [...]
Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity
23/01/2026
PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and [...]
Adagene Provides Business Update and 2026 Objectives
23/01/2026
Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated [...]
Aeroflow Health CEO Casey Hite Named to The Healthcare Technology Report’s Top Healthcare Technology CEOs of 2025 List
23/01/2026
Casey Hite is recognized for his strategic leadership in advancing healthcare technology to provide patients with better access to care ASHEVILLE, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Aeroflow Health, a pioneering [...]
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
23/01/2026
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced [...]
Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
23/01/2026
Voluntarily Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing Nes-Ziona, Israel, Jan. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Daxor Corporation Announces $9 Million Registered Direct Offering
23/01/2026
OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) (“Daxor” or the “Company”) announced today that it has entered into a definitive agreement with fundamental investors for the purchase [...]
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
23/01/2026
THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026. The event [...]
Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th
23/01/2026
Dallas, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to [...]
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
23/01/2026
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on [...]
Coloplast Finance B.V. - Decisions at the Annual General Meeting
23/01/2026
On 23 January 2026, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2024/25. In addition, EY [...]
Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique
23/01/2026
L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique Dans l'étude de phase 3 SHORE, l'amlitelimab en association avec des traitements topiques a atteint tous les critères d'évaluation principaux et [...]

Pages